BCM
ABCL icon

BlueCrest Capital Management’s AbCellera Biologics ABCL Stock Holding History

BlueCrest Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-143,307
Closed -$2.05M – 271
2021
Q4 		$2.05M Buy
+143,307
New +$2.17M 0.07% 192

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

BlueCrest Capital Management's ABCL Position: Q1 2022 in Review

BlueCrest Capital Management sold out of AbCellera Biologics (ABCL) in Q1 2022, closing a stake of 143,307 shares — an estimated $2.05M sold.

BlueCrest Capital Management first reported a position in ABCL in Q4 2021 and held it in 1 quarter. The position peaked at $2.05M in Q4 2021. 130 funds tracked by Wall St. Rank hold ABCL as of Q1 2022.

  • BlueCrest Capital Management reported no remaining AbCellera Biologics position as of Q1 2022 after selling out during the quarter.
  • BlueCrest Capital Management sold 143,307 AbCellera Biologics shares in Q1 2022, an estimated $2.05M.
  • BlueCrest Capital Management first reported a position in AbCellera Biologics in Q4 2021 and held it in 1 quarter.
  • BlueCrest Capital Management's AbCellera Biologics position peaked at $2.05M in Q4 2021.
  • 130 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2022.

Based on BlueCrest Capital Management's 13F filing for Q1 2022, filed 16 May 2022.